{"id":"NCT03430843","sponsor":"BeiGene","briefTitle":"A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma","officialTitle":"A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-01-26","primaryCompletion":"2020-12-01","completion":"2022-12-28","firstPosted":"2018-02-13","resultsPosted":"2023-12-29","lastUpdate":"2024-10-26"},"enrollment":512,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Esophageal Squamous Cell Carcinoma (ESCC)"],"interventions":[{"type":"DRUG","name":"Tislelizumab","otherNames":["BGB-A317"]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Docetaxel","otherNames":[]},{"type":"DRUG","name":"Irinotecan","otherNames":[]}],"arms":[{"label":"Tislelizumab","type":"EXPERIMENTAL"},{"label":"Investigator chosen chemotherapy (ICC)","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that had progressed during or after first line therapy.","primaryOutcome":{"measure":"Overall Survival (OS) in the Intent-to-Treat (ITT) Analysis Set","timeFrame":"Approximately 2 years and 10 months from date of first randomization","effectByArm":[{"arm":"Tislelizumab","deltaMin":8.6,"sd":null},{"arm":"Investigator Chosen Chemotherapy","deltaMin":6.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":104,"countries":["United States","Belgium","China","France","Germany","Italy","Japan","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["35442766","40179324","38414510","38240916","37846080","35785595"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":109,"n":255},"commonTop":["Anaemia","Decreased appetite","Nausea","Diarrhoea","Weight decreased"]}}